Abstract

Allogeneic stem cell transplantation of hematopoietic stem cells (HSCs) resistant to HIV-1 (CCR5 null cells) using a regimen to improve engraftment, and preferential cord chimerism of umbilical cord blood (UCB) cells homozygous for CCR5Δ32 mutation (UCBΔ32/Δ32) favors utilization of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>)-mediated mechanisms to facilitate allogeneic transplantation. Since PGE<sub>2</sub> has additional capacity to down-regulate CCR5 expression, this could enable dual effect

a) Allogeneic UCB cells heterozygous for the CCR5Δ32 mutation (UCBΔ32/wt)

b) Epigenetic down-regulation of residual CCR5 expression in synergy with improved engraftment.

Such treatment has capacity not only to improve engraftment of (UCBΔ32/wt) cells heterozygous for the CCR5Δ32 mutation but also prevent functional expression of the CCR5 chemokine receptor used by CCR5 (R5)-tropic HIV-1 to enter CD4<sup>+</sup> T cells. Provided that PGE<sub>2</sub>, or its more stable analogue dimethyl-PGE<sub>2</sub> (dmPGE<sub>2</sub>) has lasting effects in HSCs this could lead to significant increase of the number of treatable patients (frequency of heterozygous CCR5wt/Δ32 donors in US and Central and North of Europe is at least 10-fold higher than in the case of homozygous CCR5Δ32/Δ32 donors). Thus, ultimate goals is to create a functional R5-tropic HIV-1-resistant immune system through the use of optimized dmPGE<sub>2</sub>-modified UCB cells heterozygous for Δ32 mutation with improved homing, engraftment, and preferential cord chimerism with further emphasis on post-transplant amelioration of the graft versus host disease (GvHD) enabled via PGE<sub>2</sub>-mediated potentiation of regulatory T (Treg) cell-mediated suppression.

Keywords: CCR5; HIV-1; HSC; UCB; PGE<sub>2</sub>; dmPGE<sub>2</sub>; GvHD; nTregs; iTregs; Tcons; cAMP; ICER

Introduction

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation

The unprecedented power of the hematopoetic stem cell (HSC) transplantation of the CCR5Δ32/Δ32 cells resistant to HIV has been reported in 2009 to cure HIV infection in the case of leukemia patient infected with HIV ('Berlin patient' - Timothy Ray Brown) [1]. More than five years after transplantation 'Berlin patient' remains HIV free without any antiretroviral treatment (ART). Another two cases control HIV infection only temporarily after HSC transplantation of bone marrow cells treated with ART [2]. These two cases reported from Brigham and Women Hospital in Boston clearly demonstrated that use of bone marrow donor with CCR5Δ32/Δ32 cells resistant to HIV are superior to ART treatment and may purge latent reservoirs of HIV. Currently, CCR5Δ32/Δ32 HSCs promise sterilizing immunity against HIV. Since ‘Berlin patient’ is the first man cured of HIV infection, there is an urgent need to repeat transplantation using CCR5Δ32/Δ32 HSCs resistant to HIV. Importantly the Δ32 mutation at the CCR5 locus is present in Europe, with higher frequencies in the north [3] and homozygous carriers of the Δ32 mutation (CCR5Δ32/Δ32) are resistant to HIV-1 infection of R5 strain because the mutation prevents functional expression of the CCR5 chemokine receptor used by HIV-1 to enter CD4<sup>+</sup> T cells while homozygous carriers have partial resistance to HIV-1 infection of R5 strain. The concept of allogeneic stem cell transplantation of the cells resistant to HIV (CCR5 null cells) using a regimen to improve and modulate engraftment of umbilical cord blood cells (UCB) homozygous for CCR5Δ32 mutation favors utilization of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>)-mediated mechanisms to facilitate both allogeneic transplantation and downregulation of CCR5 expression (critical in (UCBΔ32/wt) cells of heterozygous donors with partial protection against HIV infection).

Inhibitory pathway of PGE<sub>2</sub> in Tcons

An important precedent of receptor mediated cAMP formation in inducible Treg (iTregs) is prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) synthesis [4]. It has been demonstrated that iTregs express cyclooxygenase-2 (COX-2) and produce PGE<sub>2</sub> upon differentiation, signaling through any of its four receptors – EP1, EP2, EP3, and EP4-often with opposing effects. EP2 and EP4 appear to be the most abundant in naïve cells isolated from peripheral blood and are up-regulated in response to activation. Recent studies have
providing significant insights, in particular, a pathway has been described in conventional CD4+ T cells (Tcons) where signaling through EP2 or EP4, with its concomitant increase in cAMP levels, leads to PKA activation and, through an EBP50-Ezrin-PAG scaffold, process phosphorylation of the C-terminal Src kinase (Csk). Phosphorylated Csk in turn inhibits Lck-mediated phosphorylation of the TCR complex, thus inhibiting TCR signaling and T cell proliferation and function (Figure 1).

Figure 1: Model of inhibitory pathway of prostaglandin E2 (PGE2) and down regulation of CCR5 in Tcons.

PGE2 mediates Treg inhibition of Tcon function through a PKA-mediated pathway:

1) In response to continuous antigen exposure, for instance in cancer and HIV, adaptive regulatory T cells express cyclooxygenase-2 (COX-2) and PGE2, which stimulates FOXP3 expression in these cells [4]. The Treg-derived PGE2 can signal through EP2 and EP4 receptors on Tcons to inhibit the function of these cells through pathway shown in Figure 1.

2) Binding of PGE2 to its receptors on Tcons stimulates adenyl cyclase activity, which increases intracellular cAMP levels and thus activates PKA. Aided by an Ezrin-EBP50-PAG scaffold, PKA phosphorylates Csk, which in turn phosphorylates Lck to inhibit its activity. Lck normally acts to promote TCR signaling; thus Lck inhibition through this PGE2-initiated pathway inhibits TCR signaling in Tcons.

3) Cyclic AMP (cAMP) underpins suppression by nTreg cells. Upon TCR activation (not shown), prostaglandin E2 (PGE2) leads to activation of adenyl cyclase, intracellular cAMP formation [5], and subsequent protein kinase A (PKA) activation (not shown) followed by the immediate, early induction of inducible cAMP early repressor (ICER) in TCR-activated Foxp3neg Tcons [6]. Analogous effect could be achieved by direct activation of adenyl cyclase (AC) by forskolin or inhibition of phosphodiesterases (PDEs) responsible for degradation of cAMP e.g. by Rolipram [6,7]. In response to cAMP/PKA, ICER is induced (after 2–4 h of delay, necessary for ICER synthesis) in the Foxp3neg Tcons and later ICER protein is enforced to the nucleus in response to cAMP/PKA where it may attenuate CCR5 expression in cAMP dependent fashion (Figure 2).

Figure 2: PGE2-mediated transcriptional attenuation of CCR5 chemokine receptor expression correlates with ICER induction.
Human monocytes were treated with PGE₂ (Figure 2) and scored for human chemokine receptor expression (left panel) in parallel with ICER expression (right panel), using RNase protection assay (Ambion). For evaluation of human chemokine receptor expression, a Ribosomal B2R8 probe set was used. Levels of chemokine receptor were evaluated after PGE₂ treatment (500 ng/ml final for 1h and 2h at 37°C in regular media). Levels of CCR5 are inversely related to the levels of ICER mRNA after PGE₂ treatment. Templates for the analysis of hL32 and human glyceraldehyde-3-phosphate dehydrogenase housekeeping genes were included to allow assessment of total RNA levels.

Unresolved questions of PGE₂-mediated down regulation of CCR5

PGE₂-mediated transcriptional attenuation of CCR5 chemokine receptor expression correlates with expression of potent transcriptional factor (TF) inducible cAMP early repressor (ICER). Our previous results indicate that PGE₂ may exert direct effects on downregulation of CCR5 expression in human peripheral blood monocytes (Figure 2). These preliminary studies suggest that in addition to ICER-mediated down regulation of interleukin 2 (IL-2) in autoreactive CD4⁺ conventional T cells (Tcons) [5-7] ICER could also transcriptionally attenuate expression of CCR5 receptor in the presence of PGE₂ (Figure 2). Therefore genome-wide analysis of the pulse treatment of dmPGE₂ for Tregs, Tcons, and HSCs and their consequent CCR5 downregulation along downregulation of other chemokines and chemokine receptors (such as CXCR4) will be informative. Furthermore, after the pulse treatment of UCB by dmPGE₂, gene expression profiling may optimize an ex vivo modulation protocol and UCB engraftment, bone marrow homing, and preferential cord chimerism in heterozygous (UCB₃₅/₂/wt) cells, which could be analyzed in humanized mice model. Potential downregulation of CCR5 expression by dmPGE₂ in UCBs from donors heterozygous for Δ32 mutation could significantly increase probability of appropriate UCB selection for bone marrow transplant in HIV infected patients with hematologic malignancies.

Prostaglandin-modulated hematopoietic stem cell transplantation

At present, the general consensus is that ‘true’ self-renewing human HSCs are found within the CD34⁺ population and that engraftment of a suitably conditioned host with a sufficient number of such cells will result in long-term multi-lineage hematopoiesis [8,9]. UCB cells are a valuable source of HSCs for use in allogeneic transplantation. Key advantages are easy availability and less stringent requirements for HLA matching. However, UCB contains an inherently limited HSC count associated with delayed time of engraftment, high graft failure rates and early mortality. PGE₂ derivative (16, 16 dimethyl prostaglandin E₂; dmPGE₂) was recently identified to be a critical regulator of HSC homeostasis [10]. Recent data have shown that brief ex vivo modulation with dmPGE₂ could improve patient outcomes by increasing the ‘effective dose’ of HSCs with preferential long-term engraftment of the dmPGE₂ treated HSCs in allogeneic transplantation [10]. Moreover, it was demonstrated that conventional T cells (Tcons) could be developed in vitro into CD4⁺CD25⁻Foxp3⁺ inducible regulatory T cells (iTregs) with an equivalent suppressive potential as naturally occurring regulatory T cells (nTregs) by continuous polyclonal activation with anti-CD3/CD28 mAbs [4,11]. During the differentiation process, the iTregs express COX-2 and produce PGE₂. Interestingly, neither resting nor activated nTregs express COX-2. The PGE₂ production from iTregs can be fully suppressed by the COX inhibitor indomethacin [4]. These data indicate that PGE₂ plays an important role in differentiation of HSCs thus releasing stringency required for HLA-matching donors with potential recipients as well as with potential role in dominant suppressive effects of iTregs expressing COX-2 with acquired ability to produce copious amounts of PGE₂, responsible for delivery of suppressive function through elevated levels of cAMP [12,13].

Conclusion

Prostaglandin E₂ (PGE₂)-mediated mechanisms, which have potential to down-regulate CCR5 expression in umbilical cord blood (UCB) cells heterozygous for CCR5Δ32 mutation (CCR5wt/Δ32), could reduce or eliminate surface expression of CCR5 (CCR5 null cells). These processes may thus facilitate allogeneic transplantation, UCB cell-engraftment, and preferential cord chimerism in parallel with CCR5 downregulation. Key advantages are higher frequency of heterozygous CCR5wt/Δ32 donors, less stringent requirements for HLA matching, and better engraftment of the cells resistant to HIV. To eliminate the need for indefinite treatment, our ultimate goal is to create a functional HIV-resistant immune system through the use of modified HSCs with emphasis on post-transplant amelioration of GvHD enabled via potentiation of regulatory T cell (Treg) cell-mediated suppression.

References


